Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus XYLOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus XYLOSE.
MERETEK UBT KIT (W/ PRANACTIN) vs XYLOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Xylose is a pentose sugar that is absorbed in the small intestine via passive diffusion and active transport. It is used to assess intestinal mucosal integrity; its absorption reflects the function of the enterocytes. After absorption, it is not metabolized and is excreted unchanged in urine, making it a marker for intestinal absorption and renal function.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
Adults: 25 g orally in 500 mL water, administered as a single dose for D-xylose absorption test.
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
Terminal elimination half-life: 1.2-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 10 hours).
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Renal: approximately 85-90% eliminated unchanged in urine; biliary/fecal: negligible (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent